{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:05:05Z","timestamp":1770746705265,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.thromres.2013.01.029","type":"journal-article","created":{"date-parts":[[2013,2,15]],"date-time":"2013-02-15T23:16:17Z","timestamp":1360970177000},"page":"313-319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition"],"prefix":"10.1016","volume":"131","author":[{"given":"Jan-Arne","family":"Bj\u00f6rkman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Zachrisson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gun-Britt","family":"Forsberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"von Bahr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00f6ran I.","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy D.","family":"Warner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Nylander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2013.01.029_bb0005","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2013.01.029_bb0010","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2013.01.029_bb0015","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2013.01.029_bb0020","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.thromres.2013.01.029_bb0025","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1093\/eurheartj\/ehr373","article-title":"Antiplatelet agents for the treatment and prevention of atherothrombosis","volume":"32","author":"Patrono","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.thromres.2013.01.029_bb0030","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/CIRCULATIONAHA.111.047498","article-title":"Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial","volume":"124","author":"Mahaffey","year":"2011","journal-title":"Circulation"},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2013.01.029_bb0035","first-page":"S241","article-title":"Antiplatelet drugs","volume":"147","author":"Born","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.thromres.2013.01.029_bb0040","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/j.1538-7836.2009.03527.x","article-title":"Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation","volume":"7","author":"Van Giezen","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.01.029_bb0045","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1755-5922.2009.00096.x","article-title":"Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist","volume":"27","author":"Husted","year":"2009","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.thromres.2013.01.029_bb0050","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-0038-1648859","article-title":"The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A","volume":"72","author":"Savi","year":"1994","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.01.029_bb0055","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1124\/dmd.110.032086","article-title":"Biotransformation of prasugrel, a novel thienopyridine antiplatelet agent, to the pharmacologically active metabolite","volume":"38","author":"Hagihara","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.thromres.2013.01.029_bb0060","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/CIRCULATIONAHA.109.919456","article-title":"Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study","volume":"121","author":"Gurbel","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2013.01.029_bb0065","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2013.01.029_bb0070","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.jacc.2007.07.058","article-title":"Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes","volume":"50","author":"Storey","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2013.01.029_bb0075","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2125.2011.03943.x","article-title":"Anti-platelet therapy: cyclo-oxygenase inhibition and use of aspirin with particular regard to dual anti-platelet therapy","volume":"72","author":"Warner","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.thromres.2013.01.029_bb0080","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/hrt.2010.205724","article-title":"Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists?","volume":"96","author":"Warner","year":"2010","journal-title":"Heart"},{"key":"10.1016\/j.thromres.2013.01.029_bb0085","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1538-7836.2009.03714.x","article-title":"Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy","volume":"8","author":"Armstrong","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.01.029_bb0090","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1538-7836.2010.04160.x","article-title":"In the presence of strong P2Y(12) receptor blockade, aspirin provides little additional inhibition of platelet aggregation","volume":"9","author":"Armstrong","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.01.029_bb0095","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1111\/j.1538-7836.2011.04453.x","article-title":"Anti-platelet effects of aspirin vary with level of P2Y(12) receptor blockade supplied by either ticagrelor or prasugrel","volume":"9","author":"Kirkby","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.01.029_bb0100","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3109\/09537104.2010.511684","article-title":"Antagonism of P2Y12 reduces physiological thromboxane levels","volume":"21","author":"Bhavaraju","year":"2010","journal-title":"Platelets"},{"key":"10.1016\/j.thromres.2013.01.029_bb0105","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1365-2141.1985.tb07467.x","article-title":"Cumulative antiplatelet effect of low-dose enteric coated aspirin","volume":"60","author":"Jakubowski","year":"1985","journal-title":"Br J Haematol"},{"key":"10.1016\/j.thromres.2013.01.029_bb0110","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1160\/TH05-10-0653","article-title":"Dose- and time-dependent antiplatelet effects of aspirin","volume":"95","author":"Perneby","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.01.029_bb0115","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jacc.2008.10.047","article-title":"Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin \"resistance\"","volume":"53","author":"Santilli","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2013.01.029_bb0120","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1172\/JCI110814","article-title":"Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man","volume":"71","author":"FitzGerald","year":"1983","journal-title":"J Clin Invest"},{"key":"10.1016\/j.thromres.2013.01.029_bb0125","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2013.01.029_bb0130","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.thromres.2009.06.029","article-title":"Comparison of ticagrelor and thienopyridine P2Y12 binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis\/hemostasis","volume":"124","author":"van Giezen","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2013.01.029_bb0135","first-page":"IV3","article-title":"An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis","volume":"83","author":"Folts","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2013.01.029_bb0140","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/j.jchromb.2010.06.018","article-title":"Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry","volume":"878","author":"Sill\u00e9n","year":"2010","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.thromres.2013.01.029_bb0145","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0378-4347(93)E0432-P","article-title":"Simplified assay for the quantification of 2,3-dinor-6-ketoprostaglandin F1\u03b1 by gas chromatography\u2013mass spectrometry","volume":"653","author":"Daniel","year":"1994","journal-title":"J Chromatogr B Biomed Appl"},{"key":"10.1016\/j.thromres.2013.01.029_bb0150","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.prostaglandins.2010.04.002","article-title":"Quantification of urinary PGEm, 6-keto PGF1\u03b1 and 2,3-dinor-6-keto PGF1\u03b1 by UFLC\u2013MS\/MS before and after exercise","volume":"93","author":"Blatnik","year":"2010","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.thromres.2013.01.029_bb0155","doi-asserted-by":"crossref","first-page":"8070","DOI":"10.1073\/pnas.95.14.8070","article-title":"Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation","volume":"95","author":"Jin","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.thromres.2013.01.029_bb0160","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.thromres.2003.08.021","article-title":"The relative importance of the ADP receptors, P2Y12 and P2Y1, in thrombin-induced platelet activation","volume":"111","author":"Nylander","year":"2003","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2013.01.029_bb0165","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial","volume":"364","author":"Diener","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2013.01.029_bb0170","first-page":"H1174","article-title":"Continuous release of vasodilator prostanoids contributes to regulation of resting forearm blood flow in humans","volume":"274","author":"Duffy","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1016\/j.thromres.2013.01.029_bb0175","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1161\/01.CIR.100.19.1951","article-title":"Contribution of vasodilator prostanoids and nitric oxide to resting flow, metabolic vasodilation, and flow-mediated dilation in human coronary circulation","volume":"100","author":"Duffy","year":"1999","journal-title":"Circulation"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384813000340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384813000340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:37:20Z","timestamp":1758735440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384813000340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0049384813000340"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2013.01.029","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2013.01.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}